15-deoxy-Δ-12,14-Prostaglandin J2
Biological Activity
Selective PPARγ agonist that induces adipocyte differentiation in C3H10Y1/2 fibroblasts (EC50 = 7 μM).
Technical Data
| M. Wt | 316.44 |
| Formula | C20H28O3 |
| Storage | Store at -20°C |
| Purity | ≥95% (HPLC) |
| CAS Number | 87893-55-8 |
| PubChem ID | 5311211 |
| InChI Key | VHRUMKCAEVRUBK-GODQJPCRSA-N |
| Smiles | O=C/1C=C[C@@H](C1=C/C=C/CCCCC)C/C=C\CCCC(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solubility | Soluble in Methyl acetate (supplied pre-dissolved - 1mg/ml) |
Preparing Stock Solutions
The following data is based on the product molecular weight 316.44. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.16 mL | 15.8 mL | 31.6 mL |
| 5 mM | 0.63 mL | 3.16 mL | 6.32 mL |
| 10 mM | 0.32 mL | 1.58 mL | 3.16 mL |
| 50 mM | 0.06 mL | 0.32 mL | 0.63 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the biological activity of the product.
Forman et al (1995) 15-Deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83 803 PMID: 8521497
Kliewer et al (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83 813 PMID: 8521498
If you know of a relevant reference for 15-deoxy-Δ-12,14-Prostaglandin J2, please let us know.
View Related Products by Product Action
Keywords: 15-deoxy-D-12,14-Prostaglandin J2, 15-deoxy-D-12,14-Prostaglandin J2 supplier, Endogenous, PPARγ, PPARgamma, agonists, Peroxisome, Proliferator-activating, Receptors, 15-deoxy-Delta-12, 14-Prostaglandin, J2, 15-deoxy-D-1214-ProstaglandinJ2, 2306, Tocris Bioscience
Citations for 15-deoxy-Δ-12,14-Prostaglandin J2
Citations are publications that use Tocris products.
Currently there are no citations for 15-deoxy-Δ-12,14-Prostaglandin J2. Do you know of a great paper that uses 15-deoxy-Δ-12,14-Prostaglandin J2 from Tocris? Please let us know.
Reviews for 15-deoxy-Δ-12,14-Prostaglandin J2
There are currently no reviews for this product. Be the first to review 15-deoxy-Δ-12,14-Prostaglandin J2 and earn rewards!
Have you used 15-deoxy-Δ-12,14-Prostaglandin J2?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Cardiovascular Research Product Guide
A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:
- Hypertension
- Thrombosis and Hemostasis
- Atherosclerosis
- Myocardial Infarction
- Ischemia/Reperfusion Injury
- Arrhythmias
- Heart Failure
Nuclear Receptors Product Listing
A collection of over 150 products for key nuclear receptors, the listing includes research tools for the study of:
- Androgen Receptors
- Estrogen Receptors
- Retinoic Acid Receptors
- Retinoid X Receptors
- Vitamin D Receptors
Epilepsy PosterNew
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
